Taysha Gene Therapies, Inc. (TSHA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-85.9%

$0.57

vs $4.00 price

Levered DCF

$0.28

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

7.06

Safe zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-16.18×	-4.81×	-1.84×	-0.6×	-2.51×	-7.81×	-799.34×
P/B	7.12×	6.05×	2.74×	104.67×	4.6×	1.87×	-6,592.87×
P/S	179.93×	51.93×	13.3×	39.7×	0×	0×	0×
EV / EBITDA	-13.52×	-4.06×	-1.17×	-0.44×	-2.04×	-3.63×	0×
Gross margin	100.0%	100.0%	100.0%	0.6%	0.0%	0.0%	0.0%
Operating margin	-1130.6%	-1097.6%	-468.8%	-5037.1%	0.0%	0.0%	0.0%
Net margin	-1115.3%	-1071.6%	-722.1%	-6635.3%	0.0%	0.0%	0.0%
Current ratio	12.23×	5.42×	4.08×	1.54×	3.08×	36.17×	0.1×
Debt / equity	0.07×	0.88×	0.82×	63.15×	0.66×	0×	0×
Interest coverage	-1,753.94×	-896.66×	-14.49×	-33.18×	-121.34×	-1,535.79×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-44.1%	-124.8%	-148.9%	-17493.6%	-183.0%	-17.1%	825.9%
Return on invested capital	-34.9%	-67.2%	-52.6%	-193.9%	-106.8%	-17.1%	929.2%
Return on assets	-31.7%	-55.7%	-64.6%	-131.5%	-81.6%	-16.6%	-7433.3%
Free cash flow yield	-5.3%	-18.9%	-39.1%	-114.0%	-31.6%	-8.5%	0.0%
Earnings yield	-6.2%	-20.6%	-54.3%	-167.1%	-39.8%	-9.2%	-0.1%
Enterprise value	$1.5B	$356.9M	$122.7M	$71.4M	$352.6M	$217.6M	$890M
Net debt / EBITDA	2.8×	0.86×	0.79×	0.17×	0.5×	4.19×	0×
Cash conversion cycle (days)	0	0	0	-1,606	0	-80,868	0